(Rac)-Opnurasib

Overview

(Rac)-Opnurasib ((Rac)-JDQ-443; (Rac)-NVP-JDQ443) is the levorotomer of Opnurasib ( HY-139612 ). Opnurasib is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Drug Derivative | Products > Signaling Pathways > Ras | Products > Signaling Pathways > PERK

Product Information

• Catalog No.: HY-139612B
• CAS No.: 2653201-38-6
• Molecular Formula: C29H28ClN7O
• Molecular Weight: 526.03
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source